304 related articles for article (PubMed ID: 29256045)
21. Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma.
Kuang Y; Schomisch SJ; Chandramouli V; Lee Z
Comp Biochem Physiol C Toxicol Pharmacol; 2006 Jun; 143(2):225-31. PubMed ID: 16581304
[TBL] [Abstract][Full Text] [Related]
22. The effect of PPAR-γ agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions.
Cheong SJ; Lee CM; Kim EM; Lim ST; Sohn MH; Jeong HJ
Nucl Med Biol; 2015 Feb; 42(2):85-91. PubMed ID: 25441255
[TBL] [Abstract][Full Text] [Related]
23. Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling.
Cooper AC; Fleming IN; Phyu SM; Smith TA
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1523-32. PubMed ID: 25579456
[TBL] [Abstract][Full Text] [Related]
24. PET Imaging of Hepatocellular Carcinomas:
Zhao J; Zhang Z; Nie D; Ma H; Yuan G; Su S; Liu S; Liu S; Tang G
Mol Imaging; 2019; 18():1536012118821032. PubMed ID: 30799682
[TBL] [Abstract][Full Text] [Related]
25. Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma.
Lee M; Ko H; Yun M
Yonsei Med J; 2018 Dec; 59(10):1143-1149. PubMed ID: 30450847
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the role of hexokinase type II in cellular proliferation and apoptosis using human hepatocellular carcinoma cell lines.
Ahn KJ; Hwang HS; Park JH; Bang SH; Kang WJ; Yun M; Lee JD
J Nucl Med; 2009 Sep; 50(9):1525-32. PubMed ID: 19690031
[TBL] [Abstract][Full Text] [Related]
27. Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2.
Kang F; Ma W; Ma X; Shao Y; Yang W; Chen X; Li L; Wang J
J Nucl Med; 2014 Mar; 55(3):439-45. PubMed ID: 24504055
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma
Xiao Q; Liu H; Wang HS; Cao MT; Meng XJ; Xiang YL; Zhang YQ; Shu F; Zhang QG; Shan H; Jiang GM
Theranostics; 2020; 10(22):10245-10261. PubMed ID: 32929346
[TBL] [Abstract][Full Text] [Related]
29. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
Ho CL; Chen S; Yeung DW; Cheng TK
J Nucl Med; 2007 Jun; 48(6):902-9. PubMed ID: 17504862
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of metabolic characteristics and viability of lipiodolized hepatocellular carcinomas using 18F-FDG PET/CT.
Kim HO; Kim JS; Shin YM; Ryu JS; Lee YS; Lee SG
J Nucl Med; 2010 Dec; 51(12):1849-56. PubMed ID: 21098794
[TBL] [Abstract][Full Text] [Related]
31. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S
Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
[TBL] [Abstract][Full Text] [Related]
32. Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma.
Pant V; Sen IB; Soin AS
Nucl Med Commun; 2013 Aug; 34(8):749-57. PubMed ID: 23689586
[TBL] [Abstract][Full Text] [Related]
33. Diffusion-weighted MRI and
Chung YH; Yu CF; Chiu SC; Chiu H; Hsu ST; Wu CR; Yang CL; Hong JH; Yen TC; Chen FH
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1733-1744. PubMed ID: 31127350
[TBL] [Abstract][Full Text] [Related]
34. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
[TBL] [Abstract][Full Text] [Related]
35. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.
Wang H; Zhang J; Tian J; Qu B; Li T; Chen Y; Liu J; Wang S
J Nucl Med; 2009 Nov; 50(11):1857-64. PubMed ID: 19837754
[TBL] [Abstract][Full Text] [Related]
36. Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma.
Zhou X; Chen J; Yi G; Deng M; Liu H; Liang M; Shi B; Fu X; Chen Y; Chen L; He Z; Wang J; Liu J
Oncotarget; 2016 Jan; 7(1):873-84. PubMed ID: 26621849
[TBL] [Abstract][Full Text] [Related]
37. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
[TBL] [Abstract][Full Text] [Related]
38. [
Bak-Fredslund KP; Keiding S; Villadsen GE; Kramer S; Schlander S; Sørensen M
Liver Int; 2020 Feb; 40(2):447-455. PubMed ID: 31705784
[TBL] [Abstract][Full Text] [Related]
39. Gα12gep oncogene inhibits FOXO1 in hepatocellular carcinoma as a consequence of miR-135b and miR-194 dysregulation.
Jung HS; Seo YR; Yang YM; Koo JH; An J; Lee SJ; Kim KM; Kim SG
Cell Signal; 2014 Jul; 26(7):1456-65. PubMed ID: 24631529
[TBL] [Abstract][Full Text] [Related]
40. F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma.
Wu HB; Wang QS; Li BY; Li HS; Zhou WL; Wang QY
Clin Nucl Med; 2011 Dec; 36(12):1092-7. PubMed ID: 22064078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
